Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (Merit-UC)

University of North Carolina (UNC)

Status and phase: Completed; Phase 2

Conditions: Ulcerative Colitis

Treatments: Drug: Methotrexate

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT01393405

1U01DK092239-01 (U.S. NIH Grant/Contract)

09-2044

Details and patient eligibility

About

There are fewer therapeutic options for patients with active ulcerative colitis (UC) compared to patients with active Crohn's disease (CD) and the investigators are facing a persistent unmet need for additional effective and affordable therapies for patients with UC. Methotrexate (MTX) 25 mg once weekly administered subcutaneously (sq) or intramuscularly (im) is an efficient therapy to induce and maintain steroid free remission in patients with CD. To evaluate the efficacy of a similar approach in patients with active ulcerative colitis the investigators conduct a double-blind, placebo controlled, randomized, multicenter, parallel group trial to investigate the safety and efficacy of 25 mg MTX applied subcutaneously once weekly in patients with active UC, who either failed 5-ASA therapy, or are steroid dependent or are intolerant or not responding to azathioprine/6-mercaptopurine therapy or have no response/ lost response to infliximab prior to the study inclusion. The study is designed as a drug withdrawal trial and includes two periods, the Induction Period (week 0-16) and the Maintenance Period (week 17-48). In the open label Induction Period every patient will receive a steroid taper, MTX 25 mg sq once weekly + daily folic acid 1 mg tablets for the induction of clinical response or remission. Patients responding to the open label MTX therapy and being off steroids between week 12-16 will be randomized at week 16 1:1 to Placebo sq once weekly + daily folic acid 1 mg tablets + 2.4 g mesalamine or to MTX 25 mg sq once weekly + daily folic acid 1 mg tablets+ 2.4 g mesalamine. The Specific Aims of the trial are: i) To evaluate the safety and tolerability of 25 mg MTX applied sq once weekly over a time period of 48 weeks; ii) To evaluate the relapse-free survival of MTX maintenance therapy compared to placebo over a time period of 32 weeks; iii) To evaluate the efficacy of MTX over a time period of 16 weeks to induce steroid free remission; iiii) To establish a DNA, plasma and serum library to enable the evaluation of clinical and pharmacogenomic models to predict the response to MTX therapy in patients with UC. With 25-30 participating centers actively enrolling, the investigators anticipate to complete enrollment for this study in a time period of 3 years. Completion of this trial will define the therapeutic value of MTX in UC, potentially changing the current therapeutic strategy in UC.

Enrollment: 179 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent.
• Man or woman between 18 and 70 years of age.
• UC diagnosed by routine clinical, radiographic, endoscopic, and pathological criteria.
• Active UC with a Mayo score of 6 to 12 points and moderate-to severe active disease on sigmoidoscopy (Mayo endoscopic subscore of at least 2)

and at least ONE of the following criteria:

• Steroid dependent UC *

• Primary failure or loss of response to an anti-TNF (infliximab, adalimumab, golimumab) in the past

• Primary failure or loss of response to vedolizumab in the past

• Intolerance/failure of azathioprine/6-MP therapy in the past

• Failure of 5-ASA therapy

  • Steroid dependence is defined as a clinical response to treatment with prednisone 40 to 60 mg/day and relapse within 30 days after prednisone treatment was completed or as a requirement for a daily dosage of not less than 10 mg of prednisone and impossibility of weaning the patient off steroid without clinical relapses (two attempts to discontinue the medication within the preceding six months of the start of the study).

Exclusion criteria

• Failure to respond to 40 mg of prednisone or higher/day in the last 2 weeks before inclusion
• Concomitant use of azathioprine (AZA) or 6-mercaptopurine (6-MP) must be discontinued at least 2 weeks before inclusion into the study (Week 0 visit)
• Anti-TNF therapy in the 2 weeks before the Week 0 visit
• Failure of cyclosporine therapy in the previous 6 months prior to Screening visit
• Patients with serum albumin < 2.5 g/dl at baseline
• Low serum folate defined as decrease of >10% below normal range
• Patients with WBC< 3.0 x109th/L at baseline
• Patients with platelet count < 100 x109th/L
• Patients with an underlying infection with C. difficile at Screening visit
• Patients with pre-existing hepatic disease
• Patients with known non-alcoholic fatty liver disease (NAFLD)
• Patients with known Hepatitis B or Hepatitis C
• Patients with pre-existing renal dysfunction (creatinine >1.5 mg/dl).
• Patients with a pre-existing chronic lung disease other than well controlled asthma
• Patients with interstitial lung disease of unknown cause
• Patients with a BMI >35
• Known previous or concurrent malignancy (other than that considered surgically cured, with no evidence for recurrence for 5 years - basal cell does not exclude)
• Existing pregnancy, lactation, or planned pregnancy* (men and women) within the next 12 months. (*Methotrexate should not be used for at least 3 months before planned pregnancy for men and women and should not be used during pregnancy or breast feeding)
• High alcohol consumption (more than seven drinks per week)
• Non - steroidal inflammatory medications (NSAIDs) as long-term treatment, defined as use for at least 4 days a week each month
• Continuous treatment with one of the following drugs:
• Probenecid,
• Trimethoprim/sulfamethoxazole
• Sulfasalazine
• Acitretin
• Streptozocin
• Non-use of appropriate contraceptives in females of childbearing potential (e.g. condoms, intrauterine device {IUD}, hormonal contraception, or other means considered adequate by the responsible investigator) or in males with a child-fathering potential (condoms, or other means considered adequate by the responsible investigator during treatment
• Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial
• Well-founded doubt about the patient's cooperation.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

179 participants in 2 patient groups, including a placebo group

Methotrexate

Active Comparator group

Description:

25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine

Treatment:

Drug: Methotrexate

Placebo

Placebo Comparator group

Description:

Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine

Treatment:

Drug: Methotrexate